Search results for " antifungal"

showing 10 items of 37 documents

Inhibition of Metarhizium anisopliae in the alimentary tract of the eastern subterranean termite Reticulitermes flavipes

2009

Reticulitermes flavipes workers were individually inoculated with 10,000 conidia of the entomopathogenic fungus Metarhizium anisopliae. After being kept in groups of 20 individuals for 1–6 d, histopathological approach showed that most of the inoculated conidia were groomed from the surface of the cuticle by nestmates within 24 h, and that a large number of conidia was subsequently found in different parts of the gut of the groomers. Our observations showed that, among thousands of conidia found in the termite's gut, conidial germination never occurred in all inspected specimens, even when the conidia had the chance to bind to the surface of the cuticular lining of the gut. In addition, whe…

0106 biological sciencesHyphal growthMetarhiziumMetarhizium anisopliaeIsoptera01 natural sciencesConidiumMicrobiology03 medical and health sciencesReticulitermesSpore germinationAnimalsSocial BehaviorEcology Evolution Behavior and Systematics030304 developmental biology0303 health sciencesbiologyfungibiology.organism_classificationGroomingImmunity InnateTermite Metarhizium Disease resistance Antifungal activity Gut010602 entomologyEastern subterranean termiteMetarhizium[SDE.BE]Environmental Sciences/Biodiversity and EcologyDigestive SystemRhinotermitidae
researchProduct

Lactic Acid Bacteria Isolation from Spontaneous Sourdough and Their Characterization Including Antimicrobial and Antifungal Properties Evaluation

2019

This research effort aimed at isolating and phenotypically characterizing lactic acid bacteria (LAB) isolates from a spontaneous rye sourdough manufactured following traditional protocols, as well as at evaluating their antimicrobial and antifungal properties as key features for future industrial applications. Thirteen LAB strains of potential industrial interest were isolated and identified to species-level via PCR. Most of the sourdough isolates showed versatile carbohydrate metabolisms. The Leuconostoc mesenteroides No. 242 and Lactobacillus brevis No. 173 demonstrated to be gas producers

0106 biological sciencesMicrobiology (medical)Pediococcus</i>Lactobacillus caseiLactobacillus paracasei<i>Lactobacillus01 natural sciencesMicrobiologyArticleinhibition of bacterial pathogens0404 agricultural biotechnology010608 biotechnologyVirologyLactobacillusLeuconostoc<i>pediococcus</i>carbohydrate metabolismFood sciencePediococcus<i>lactobacillus</i>lcsh:QH301-705.5antimicrobial activitybiologyLactobacillus brevisantifungal activityfood and beverages04 agricultural and veterinary sciencesbiology.organism_classificationAntimicrobial040401 food sciencelactic acid bacteriaLactobacilluslcsh:Biology (General)<i>leuconostoc</i>spontaneous sourdoughPediococcusspontaneous sourdough ; lactic acid bacteria ; Lactobacillus ; Leuconostoc ; Pediococcus ; antimicrobial activity ; antifungal activity ; inhibition of bacterial pathogens ; carbohydrate metabolismLactobacillus plantarumLeuconostocMicroorganisms
researchProduct

Candida blood stream infections observed between 2011 and 2016 in a large Italian University Hospital: A time-based retrospective analysis on epidemi…

2019

Candida bloodstream infection (BSI) represents a growing infective problem frequently associated to biofilm production due to the utilization of intravascular devices. Candida species distribution (n = 612 strains), their biofilm production and hospital antifungal drug consumption were evaluated in different wards of a tertiary care academic hospital in Italy during the years 2011–2016. In the considered time window, an increasing number of Candida BSI (p = 0.005) and of biofilm producing strains were observed (p<0.0001). Although C. albicans was the species more frequently isolated in BSI with a major biofilm production, an increased involvement of non-albicans species was reported, partic…

0301 basic medicineAntifungal AgentsTime FactorsAntifungal drugYeast and Fungal ModelsPathology and Laboratory Medicinelaw.inventionHospitals Universitychemistry.chemical_compound0302 clinical medicinelawAmphotericin BMedicine and Health Sciences030212 general & internal medicineAmphotericinFluconazoleCandidaFungal PathogensPrincipal Component AnalysisMultidisciplinaryAntimicrobialsQCandidiasisREukaryotaDrugsIntensive care unitHospitalsCorpus albicansIntensive Care UnitsExperimental Organism SystemsItalyMedical MicrobiologyEngineering and TechnologyMedicinePathogensResearch ArticleBiotechnologymedicine.drugCandida Candida bloodstream infection biofilm antifungal agents drug susceptibilityCathetersScience030106 microbiologyBioengineeringMycologyMicrobial Sensitivity TestsResearch and Analysis MethodsMicrobiologyMicrobiology03 medical and health sciencesMicrobial ControlmedicineCandida AlbicansHumansMicrobial PathogensRetrospective StudiesPharmacologyVoriconazoleAntifungalsbusiness.industryOrganismsFungiBiofilmBiology and Life SciencesYeastHealth CarechemistryHealth Care FacilitiesBiofilmsAnimal StudiesMedical Devices and EquipmentAntimicrobial ResistanceCaspofunginbusinessFluconazolePLOS ONE
researchProduct

Assessment of the Antimicrobial Activity and the Entomocidal Potential of Bacillus thuringiensis Isolates from Algeria.

2017

This work represents the first initiative to analyze the distribution of B. thuringiensis in Algeria and to evaluate the biological potential of the isolates. A total of 157 isolates were recovered, with at least one isolate in 94.4% of the samples. The highest Bt index was found in samples from rhizospheric soil (0.48) and from the Mediterranean area (0.44). Most isolates showed antifungal activity (98.5%), in contrast to the few that had antibacterial activity (29.9%). A high genetic diversity was made evident by the finding of many different crystal shapes and various combinations of shapes within a single isolate (in 58.4% of the isolates). Also, over 50% of the isolates harbored cry1, …

0301 basic medicineAntifungalStaphylococcus aureusmedicine.drug_classHealth Toxicology and Mutagenesis030106 microbiologyBacterial ToxinsBiological pest controlBacillus thuringiensisBiologyToxicologyArticleMicrobiology03 medical and health sciencesB. thuringiensisAnti-Infective AgentsBacterial ProteinsBacillus thuringiensismedicineEscherichia colibiocontrolGeneSoil MicrobiologyGenetic diversitycryChitinasesFungi<i>B. thuringiensis</i>; antibacterial; antifungal; <i>cry</i>; <i>vip3</i>; chitinase; biocontrolAntimicrobialbiology.organism_classificationCryptochromesantibacterialHexosaminidasesGenes BacterialAlgeriachitinaseChitinasePseudomonas aeruginosavip3biology.proteinMicroscopy Electron ScanningAntibacterial activityantifungalToxins
researchProduct

Should we continue to use prediction tools to identify patients at risk of Candida spp. infection? If yes, why?

2016

Background Given the predominance of invasive fungal disease (IFD) amongst the non-immunocompromised adult critically ill population, the potential benefit of antifungal prophylaxis and the lack of generalisable tools to identify high risk patients, the aim of the current study was to describe the epidemiology of IFD in UK critical care units, and to develop and validate a clinical risk prediction tool to identify non-neutropenic, critically ill adult patients at high risk of IFD who would benefit from antifungal prophylaxis. Methods Data on risk factors for, and outcomes from, IFD were collected for consecutive admissions to adult, general critical care units in the UK participating in the…

0301 basic medicineCandida spp; Invasive fungal infections; Sepsismedicine.medical_specialtyAntifungal AgentsSepsi030106 microbiologyMycoseSubgroup analysisCritical Care and Intensive Care Medicinelaw.inventionSepsis03 medical and health sciences0302 clinical medicineInvasive fungal infectionRandomized controlled trialRisk FactorsInvasive fungal infectionslawSepsisIntensive caremedicineHumansAntifungal Agent030212 general & internal medicineMED/41 - ANESTESIOLOGIAIntensive care medicineCandidaCandida sppProphylaxisbusiness.industryIncidence (epidemiology)Risk FactorCandidiasismedicine.diseaseConfidence intervalCritical careFungalMycosesRelative riskCandida sppCandidiasiCandida spp; Invasive fungal infections; Sepsis; Antifungal Agents; Candida; Humans; Risk Factors; Candidiasis; Mycoses; Critical Care and Intensive Care MedicineInvasive fungal diseasebusinessResearch ArticleHuman
researchProduct

MEDical wards Invasive Candidiasis ALgorithms (MEDICAL):Consensus proposal for management

2016

Abstract Introduction A majority of invasive Candida infections occur in medical wards; however, evidence for management in this setting is scarce and based primarily on the intensive care or surgical setting. On behalf of the Italian Society for Anti-Infective Therapy (SITA) and the Italian Federation of Associations of Hospital Doctors on Internal Medicine (FADOI), the MEDICAL group produced practical management algorithms for patients in internal medicine wards. Methods The MEDICAL group panel, composed of 30 members from internal medicine, infectious disease, clinical pharmacology, clinical microbiology and clinical epidemiology, provided expert opinion through the RAND/UCLA method. Res…

0301 basic medicineMedical wardAntifungal AgentsConsensusInvasiveCritical CareDelphi TechniqueClinical severity; Invasive candidiasis; Medical wards; Risk stratification; Algorithms; Antifungal Agents; Candidiasis Invasive; Consensus; Critical Care; Delphi Technique; Early Diagnosis; Echinocandins; Humans; Internal Medicine; Italy; Practice Guidelines as Topic; Severity of Illness Index; Internal Medicine030106 microbiologyeducationDelphi methodInvasive candidiasiSettore MED/17 - MALATTIE INFETTIVESeverity of Illness Indexlaw.invention03 medical and health sciencesEchinocandins0302 clinical medicinelawIntensive careSeverity of illnessMedical consensusInternal MedicineMedicineHumansCandidiasis InvasiveClinical severity030212 general & internal medicineRisk stratificationcomputer.programming_languageClinical pharmacologybusiness.industryCandidiasisClinical severity; Invasive candidiasis; Medical wards; Risk stratificationInvasive candidiasismedicine.diseaseMedical wardsInvasive candidiasisEarly DiagnosisItalyInfectious disease (medical specialty)Practice Guidelines as TopicbusinessClinical severity; Invasive candidiasis; Medical wards; Risk stratification; Internal MedicinecomputerAlgorithmDelphiAlgorithms
researchProduct

Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris

2018

Abstract Candida spp. infections are a major cause of morbidity and mortality in critically ill patients. Candida auris is an emerging multi-drug-resistant fungus that is rapidly spreading worldwide. Since the first reports in 2009, many isolates across five continents have been identified as agents of hospital-associated infections. Independent and simultaneous outbreaks of C. auris are becoming a major concern for healthcare and scientific community. Moreover, laboratory misidentification and multi-drug-resistant profiles, rarely observed for other non-albicans Candida species, result in difficult eradication and frequent therapeutic failures of C. auris infections. The aim of this review…

0301 basic medicineSettore MED/07 - Microbiologia E Microbiologia Clinicamedicine.medical_specialty030106 microbiologySettore MED/41 - AnestesiologiaVirulenceAntimicrobial resistanceCritical Care and Intensive Care MedicineMicrobiology03 medical and health sciencesInvasive fungal infectionAntibiotic resistanceEpidemiologymedicineCandidaResistance (ecology)business.industryCritically illlcsh:Medical emergencies. Critical care. Intensive care. First aidCandidemiaOutbreakAntifungal resistancelcsh:RC86-88.9Candida aurisCandida sppC. aurisC. auris Candida Candidemia Invasive fungal infection Antimicrobial resistance Antifungal resistancebusinessJournal of Intensive Care
researchProduct

Is it time to combine untargeted antifungal strategies to reach the goal of 'early' effective treatment?

2016

A recently published retrospective study by Posteraro et al. [1] investigated the use of (1–3)-β-D-glucan (BDG) as a strategy for antifungal drug administration in patients at high risk of candidemia. The strategy consisted of the administration of antifungals (anidulafungin in most cases) to septic patients with a Candida score ≥ 3a nd a positive BDG result (≥80 pg/ml). This untargeted strategy led to better selection of patients, avoiding exposure to antifungals in approximately 73 % of patients with negative BDG results and leading to shortened treatment duration in another 20 % of patients. Untargeted antifungal treatments (including prophylaxis, pre-emptive and empiric approaches) are …

0301 basic medicinemedicine.medical_specialtyAntifungal Agents030106 microbiologyAntifungal drugCritical Care and Intensive Care Medicinelaw.inventionGoal03 medical and health sciences0302 clinical medicineRandomized controlled triallawmedicineHumans; Treatment Outcome; Antifungal Agents; Goals; Critical Care and Intensive Care MedicineAntifungal AgentHumansStage (cooking)MED/41 - ANESTESIOLOGIAAdverse effectIntensive care medicineSurrogate endpointbusiness.industryIncidence (epidemiology)030208 emergency & critical care medicineRetrospective cohort studyTreatment OutcomeAnidulafunginbusinessGoalsmedicine.drugHumanCritical care (London, England)
researchProduct

Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients

2016

Background Invasive fungal infections are important causes of morbidity and mortality among critically ill patients. Early institution of antifungal therapy is pivotal for mortality reduction. Starting a targeted antifungal therapy after culture positivity and fungi identification requires a long time. Therefore, alternative strategies (globally defined as 'untargeted antifungal treatments') for antifungal therapy institution in patients without proven microbiological evidence of fungal infections have been discussed by international guidelines. This review was originally published in 2006 and updated in 2016. This updated review provides additional evidence for the clinician dealing with s…

Adultmedicine.medical_specialtyAntifungal drugMycoseintensive care medicinelaw.invention03 medical and health sciencesImmunocompromised Hostcritically ill patient0302 clinical medicineRandomized controlled triallawInternal medicineAmphotericin BmedicineHumansAntifungal AgentPharmacology (medical)030212 general & internal medicineMED/41 - ANESTESIOLOGIAIntensive care medicineFluconazoleFluconazole [therapeutic use]Randomized Controlled Trials as Topicbusiness.industryfungal infectionMicafungin030208 emergency & critical care medicinePublication biasMycoses [mortalityClinical trialCritical Illness [mortality]; Amphotericin B [therapeutic use]; Antifungal Agents [therapeutic use]; Fluconazole [therapeutic use]; Immunocompromised Host; Mycoses [mortality; prevention & control]; Randomized Controlled Trials as Topic; Adult; HumansAntifungal Agents [therapeutic use]prevention & control]Relative riskMeta-analysisAmphotericin B [therapeutic use]AnidulafunginCritical IllneCritical Illness [mortality]businessmedicine.drugHuman
researchProduct

Low dosage liposomal amphotericin B in the treatment of Candida infections in critically ill patients.

2011

Antifungal AgentsTreatment OutcomeCritical care candida sepsisAmphotericin BCritical IllnessCandidiasisHumansSettore MED/41 - AnestesiologiaPilot ProjectsAmphotericin B; administration /&/ dosage Antifungal Agents; administration /&/ dosage Candidiasis; drug therapy Critical Illness Humans Middle Aged Pilot Projects Treatment OutcomeMiddle Agedadministration /&/ dosagedrug therapy
researchProduct